Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX)

Susquehanna International Group LLP grew its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 769.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,115,748 shares of the company's stock after buying an additional 987,475 shares during the quarter. Susquehanna International Group LLP owned 0.77% of Biodesix worth $1,707,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its stake in shares of Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company's stock valued at $41,000 after acquiring an additional 21,179 shares during the period. MYDA Advisors LLC purchased a new stake in Biodesix in the 4th quarter worth about $76,000. HighTower Advisors LLC lifted its stake in Biodesix by 17.1% in the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company's stock worth $236,000 after purchasing an additional 22,500 shares during the last quarter. Stephens Inc. AR purchased a new position in shares of Biodesix during the fourth quarter valued at approximately $303,000. Finally, Renaissance Technologies LLC boosted its position in shares of Biodesix by 775.2% during the fourth quarter. Renaissance Technologies LLC now owns 360,200 shares of the company's stock valued at $551,000 after buying an additional 319,043 shares during the period. Institutional investors own 20.96% of the company's stock.

Biodesix Trading Up 15.0%

Shares of NASDAQ BDSX traded up $0.03 during trading hours on Friday, reaching $0.25. The stock had a trading volume of 9,423,104 shares, compared to its average volume of 816,935. Biodesix, Inc. has a 52-week low of $0.17 and a 52-week high of $2.04. The firm has a market cap of $37.05 million, a price-to-earnings ratio of -0.65 and a beta of 1.18. The business's fifty day moving average price is $0.58 and its two-hundred day moving average price is $1.00. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $17.96 million during the quarter, compared to analysts' expectations of $19.50 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. Analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BDSX shares. William Blair reiterated a "market perform" rating on shares of Biodesix in a report on Wednesday. Craig Hallum reduced their target price on Biodesix from $3.00 to $1.50 and set a "buy" rating on the stock in a research note on Wednesday. Canaccord Genuity Group decreased their target price on Biodesix from $2.50 to $1.50 and set a "buy" rating for the company in a research report on Wednesday. Finally, Lake Street Capital lowered their target price on shares of Biodesix from $3.00 to $2.00 and set a "buy" rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $2.00.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.